Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 60

1.

Selective PRMT5 inhibitors suppress human CD8+ T-cells by upregulation of p53 and impairment of the AKT pathway similar to the tumor metabolite MTA.

Strobl CD, Schaffer S, Haug T, Völkl S, Peter K, Singer K, Böttcher M, Mougiakakos D, Mackensen A, Aigner M.

Mol Cancer Ther. 2019 Nov 11. pii: molcanther.0189.2019. doi: 10.1158/1535-7163.MCT-19-0189. [Epub ahead of print]

PMID:
31712395
2.

PGAM5 is a key driver of mitochondrial dysfunction in experimental lung fibrosis.

Ganzleben I, He GW, Günther C, Prigge ES, Richter K, Rieker RJ, Mougiakakos D, Neurath MF, Becker C.

Cell Mol Life Sci. 2019 Dec;76(23):4783-4794. doi: 10.1007/s00018-019-03133-1. Epub 2019 Jun 5.

PMID:
31168659
3.

Human Double-Negative Regulatory T-Cells Induce a Metabolic and Functional Switch in Effector T-Cells by Suppressing mTOR Activity.

Haug T, Aigner M, Peuser MM, Strobl CD, Hildner K, Mougiakakos D, Bruns H, Mackensen A, Völkl S.

Front Immunol. 2019 Apr 26;10:883. doi: 10.3389/fimmu.2019.00883. eCollection 2019.

4.

Energy metabolism is co-determined by genetic variants in chronic lymphocytic leukemia and influences drug sensitivity.

Lu J, Böttcher M, Walther T, Mougiakakos D, Zenz T, Huber W.

Haematologica. 2019 Sep;104(9):1830-1840. doi: 10.3324/haematol.2018.203067. Epub 2019 Feb 21.

5.

A novel immunoregulatory function of beta-2-microglobulin as a promoter of myeloid derived suppressor cell induction.

Bruns H, Jitschin S, Gamali S, Saul D, Böttcher M, Mackensen A, Jitschin R, Mougiakakos D.

Leukemia. 2019 May;33(5):1282-1287. doi: 10.1038/s41375-018-0345-0. Epub 2019 Jan 11. No abstract available.

PMID:
30635624
6.

CD33/CD3-bispecific T-cell engaging (BiTE®) antibody construct targets monocytic AML myeloid-derived suppressor cells.

Jitschin R, Saul D, Braun M, Tohumeken S, Völkl S, Kischel R, Lutteropp M, Dos Santos C, Mackensen A, Mougiakakos D.

J Immunother Cancer. 2018 Nov 5;6(1):116. doi: 10.1186/s40425-018-0432-9.

7.

Regulation of Energy Metabolism during Early B Lymphocyte Development.

Urbanczyk S, Stein M, Schuh W, Jäck HM, Mougiakakos D, Mielenz D.

Int J Mol Sci. 2018 Jul 27;19(8). pii: E2192. doi: 10.3390/ijms19082192. Review.

8.

D-2-hydroxyglutarate interferes with HIF-1α stability skewing T-cell metabolism towards oxidative phosphorylation and impairing Th17 polarization.

Böttcher M, Renner K, Berger R, Mentz K, Thomas S, Cardenas-Conejo ZE, Dettmer K, Oefner PJ, Mackensen A, Kreutz M, Mougiakakos D.

Oncoimmunology. 2018 Mar 26;7(7):e1445454. doi: 10.1080/2162402X.2018.1445454. eCollection 2018.

9.

Lenalidomide enhances MOR202-dependent macrophage-mediated effector functions via the vitamin D pathway.

Busch L, Mougiakakos D, Büttner-Herold M, Müller MJ, Volmer DA, Bach C, Fabri M, Bittenbring JT, Neumann F, Boxhammer R, Nolting J, Bisht S, Böttcher M, Jitschin S, Hoffmann MH, Balzer H, Beier F, Gezer D, Dudziak D, Gelse K, Hennig FF, Pallasch CP, Spriewald B, Mackensen A, Bruns H.

Leukemia. 2018 Nov;32(11):2445-2458. doi: 10.1038/s41375-018-0114-0. Epub 2018 Mar 28.

PMID:
29654274
10.

Phenotypic and functional alterations of myeloid-derived suppressor cells during the disease course of multiple sclerosis.

Iacobaeus E, Douagi I, Jitschin R, Marcusson-Ståhl M, Andrén AT, Gavin C, Lefsihane K, Davies LC, Mougiakakos D, Kadri N, Le Blanc K.

Immunol Cell Biol. 2018 Sep;96(8):820-830. doi: 10.1111/imcb.12042. Epub 2018 Apr 19.

PMID:
29569304
11.

IL-21 modulates memory and exhaustion phenotype of T-cells in a fatty acid oxidation-dependent manner.

Loschinski R, Böttcher M, Stoll A, Bruns H, Mackensen A, Mougiakakos D.

Oncotarget. 2018 Feb 7;9(17):13125-13138. doi: 10.18632/oncotarget.24442. eCollection 2018 Mar 2.

12.

Polyol Pathway Links Glucose Metabolism to the Aggressiveness of Cancer Cells.

Schwab A, Siddiqui A, Vazakidou ME, Napoli F, Böttcher M, Menchicchi B, Raza U, Saatci Ö, Krebs AM, Ferrazzi F, Rapa I, Dettmer-Wilde K, Waldner MJ, Ekici AB, Rasheed SAK, Mougiakakos D, Oefner PJ, Sahin O, Volante M, Greten FR, Brabletz T, Ceppi P.

Cancer Res. 2018 Apr 1;78(7):1604-1618. doi: 10.1158/0008-5472.CAN-17-2834. Epub 2018 Jan 17.

13.

Short-chain fatty acids regulate systemic bone mass and protect from pathological bone loss.

Lucas S, Omata Y, Hofmann J, Böttcher M, Iljazovic A, Sarter K, Albrecht O, Schulz O, Krishnacoumar B, Krönke G, Herrmann M, Mougiakakos D, Strowig T, Schett G, Zaiss MM.

Nat Commun. 2018 Jan 4;9(1):55. doi: 10.1038/s41467-017-02490-4.

14.

Linking CREB function with altered metabolism in murine fibroblast-based model cell lines.

Steven A, Leisz S, Wickenhauser C, Schulz K, Mougiakakos D, Kiessling R, Denkert C, Seliger B.

Oncotarget. 2017 Oct 27;8(57):97439-97463. doi: 10.18632/oncotarget.22135. eCollection 2017 Nov 14.

15.

In mammalian skeletal muscle, phosphorylation of TOMM22 by protein kinase CSNK2/CK2 controls mitophagy.

Kravic B, Harbauer AB, Romanello V, Simeone L, Vögtle FN, Kaiser T, Straubinger M, Huraskin D, Böttcher M, Cerqua C, Martin ED, Poveda-Huertes D, Buttgereit A, Rabalski AJ, Heuss D, Rudolf R, Friedrich O, Litchfield D, Marber M, Salviati L, Mougiakakos D, Neuhuber W, Sandri M, Meisinger C, Hashemolhosseini S.

Autophagy. 2018;14(2):311-335. doi: 10.1080/15548627.2017.1403716. Epub 2018 Feb 1.

16.

PD-L1/PD-1: new kid on the "immune metabolic" block.

Qorraj M, Böttcher M, Mougiakakos D.

Oncotarget. 2017 Sep 5;8(43):73364-73365. doi: 10.18632/oncotarget.20639. eCollection 2017 Sep 26. No abstract available.

17.

A defined metabolic state in pre B cells governs B-cell development and is counterbalanced by Swiprosin-2/EFhd1.

Stein M, Dütting S, Mougiakakos D, Bösl M, Fritsch K, Reimer D, Urbanczyk S, Steinmetz T, Schuh W, Bozec A, Winkler TH, Jäck HM, Mielenz D.

Cell Death Differ. 2017 Jul;24(7):1239-1252. doi: 10.1038/cdd.2017.52. Epub 2017 May 19.

18.

The EMT-activator Zeb1 is a key factor for cell plasticity and promotes metastasis in pancreatic cancer.

Krebs AM, Mitschke J, Lasierra Losada M, Schmalhofer O, Boerries M, Busch H, Boettcher M, Mougiakakos D, Reichardt W, Bronsert P, Brunton VG, Pilarsky C, Winkler TH, Brabletz S, Stemmler MP, Brabletz T.

Nat Cell Biol. 2017 May;19(5):518-529. doi: 10.1038/ncb3513. Epub 2017 Apr 17.

PMID:
28414315
19.

Suppressive effects of tumor cell-derived 5'-deoxy-5'-methylthioadenosine on human T cells.

Henrich FC, Singer K, Poller K, Bernhardt L, Strobl CD, Limm K, Ritter AP, Gottfried E, Völkl S, Jacobs B, Peter K, Mougiakakos D, Dettmer K, Oefner PJ, Bosserhoff AK, Kreutz MP, Aigner M, Mackensen A.

Oncoimmunology. 2016 Jun 10;5(8):e1184802. doi: 10.1080/2162402X.2016.1184802. eCollection 2016 Aug.

20.

Hypoxia-mediated alterations and their role in the HER-2/neuregulated CREB status and localization.

Steven A, Leisz S, Sychra K, Hiebl B, Wickenhauser C, Mougiakakos D, Kiessling R, Denkert C, Seliger B.

Oncotarget. 2016 Aug 9;7(32):52061-52084. doi: 10.18632/oncotarget.10474.

Supplemental Content

Loading ...
Support Center